DUBLIN--(BUSINESS WIRE)--The 'MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032' report has been added to ResearchAndMarkets.com's offering.

都柏林——（商业新闻短讯）——ResearchAndMarkets.com的产品中增加了“按MRSA类型、药物类别、疾病适应症、给药途径、分销渠道和地区划分的MRSA药物市场2024-2032”报告。

The global MRSA drugs market size reached US$ 3.8 billion in 2023. The market is projected to reach US$ 5.0 billion by 2032, exhibiting a growth rate (CAGR) of 3.2% during 2023-2032

2023年，全球MRSA药物市场规模达到38亿美元。预计到2032年，该市场将达到50亿美元，2023-2032年的复合年增长率（CAGR）为3.2%

The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.

抗生素耐药菌株发展的流行率不断上升，由于住院时间延长而持续暴露于医疗机构中的多药耐药菌以及越来越多的临床试验是推动市场的一些关键因素。

The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market.

大众中抗生素耐药菌株发展的流行率上升是推动市场增长的重要因素。这可归因于全球医院获得性感染（HAI）病例数量的增加。此外，由于住院时间延长，医疗机构中持续暴露于耐多药微生物，导致继发性医院感染的发展，从而推动了市场。

In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market..

除此之外，越来越多的老年人更容易感染MRSA，这为市场提供了动力。。

Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market.

此外，提高对不同形式细菌感染的认识正在导致MRSA药物的更高吸收。与此相一致的是，大量的产品创新，越来越多的临床试验和新型药物变体的引入正在市场上创造利润丰厚的增长机会。

However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook..

然而，开发新型MRSA药物变体所涉及的高成本是市场的主要增长抑制因素。相反，各种诊断工具的不断技术发展，以及用于筛选抗生素耐药菌株的临床试验项目的数量不断增加，正在创造积极的市场前景。。

The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure..

主要参与者进行的广泛研究与开发（R＆D）活动进一步推动了市场。促成市场的其他一些因素包括针对现有产品的仿制药的出现，在线和离线组织平台上抗生素的容易获得，快速城市化以及医疗支出的增加。。

North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.

北美是MRSA药物的最大市场。推动北美MRSA药物市场的一些因素包括医疗支出的增加，临床试验项目数量的增加，关键参与者进行的广泛研究和开发（R＆D）活动等。

Key Market Segmentation:

主要市场细分：

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type. This includes Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA). According to the report, Hospital-Acquired (HA-MRSA) represented the largest segment.

该报告根据MRSA类型提供了MRSA药物市场的详细细分和分析。这包括医院获得性（HA-MRSA）和社区获得性（CA-MRSA）。根据该报告，医院获得性（HA-MRSA）是最大的细分市场。

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the drug class. This includes lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and others. According to the report, lipopeptides represented the largest segment.

该报告根据药物类别对MRSA药物市场进行了详细的细分和分析。这包括脂肽，恶唑烷酮，头孢菌素，四环素，叶酸拮抗剂等。根据该报告，脂肽是最大的部分。

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the disease indication. This includes skin infections, bone and joint infections, bacteremia, and animal infections. According to the report, skin Infections represented the largest segment.

该报告根据疾病适应症对MRSA药物市场进行了详细的细分和分析。这包括皮肤感染、骨骼和关节感染、菌血症和动物感染。根据该报告，皮肤感染是最大的部分。

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration. This includes oral administration and parenteral administration. According to the report, parenteral administration represented the largest segment.

该报告根据给药途径对MRSA药物市场进行了详细的细分和分析。这包括口服和肠胃外给药。根据该报告，肠胃外给药是最大的部分。

A detailed breakup and analysis of the MRSA drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

该报告还提供了基于分销渠道的MRSA药物市场的详细细分和分析。这包括医院药房、零售药房和在线药房。据报道，医院药房占据了最大的市场份额。

Key Questions Answered in This Report:

本报告回答的关键问题：

How has the global MRSA drugs market performed so far and how will it perform in the coming years?

到目前为止，全球耐甲氧西林金黄色葡萄球菌药物市场表现如何，未来几年将如何？

What are the drivers, restraints, and opportunities in the global MRSA drugs market?

全球MRSA药物市场的驱动因素、限制因素和机会是什么？

What are the key regional markets?

关键的区域市场是什么？

Which countries represent the most attractive MRSA drugs markets?

哪些国家代表了最具吸引力的MRSA药物市场？

What is the breakup of the market based on the MRSA type?

基于MRSA类型的市场细分是什么？

What is the breakup of the market based on the drug class?

基于药物类别的市场细分是什么？

What is the breakup of the market based on the disease indication?

基于疾病指征的市场细分是什么？

What is the breakup of the market based on the route of administration?

基于管理路线的市场分裂是什么？

What is the breakup of the market based on the distribution channel?

基于分销渠道的市场细分是什么？

What is the competitive structure of the global MRSA drugs market?

全球MRSA药物市场的竞争结构是什么？

Who are the key players/companies in the global MRSA drugs market?

谁是全球MRSA药物市场的关键参与者/公司？

Company Analysis

公司分析

AbbVie Inc.

AbbVie股份有限公司。

Basilea Pharmaceutica Ltd

巴西莱制药有限公司

Crystal Genomics Inc.

Crystal Genomics公司。

Cumberland Pharmaceuticals Inc.

坎伯兰制药公司。

Melinta Therapeutics Inc

梅林塔治疗公司

Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals股份有限公司。

Pfizer Inc

辉瑞公司

For more information about this report visit https://www.researchandmarkets.com/r/7o8qv

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/7o8qv

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。